New lung drug faces off against standard treatment in major trial
NCT ID NCT07284602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, LYT-100, against an existing one (pirfenidone) for idiopathic pulmonary fibrosis, a lung disease that gets worse over time. About 1,100 adults will take either drug three times daily for up to a year, and researchers will measure how well their lungs function. The goal is to see if LYT-100 slows lung decline better than the current treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.